Bank of Montreal Can Has $7.46 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Bank of Montreal Can reduced its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 23.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 68,661 shares of the specialty pharmaceutical company’s stock after selling 20,852 shares during the period. Bank of Montreal Can owned 0.11% of Jazz Pharmaceuticals worth $7,455,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its position in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter worth $29,000. Rubric Capital Management LP acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter worth $65,812,000. Baupost Group LLC MA raised its position in shares of Jazz Pharmaceuticals by 52.8% during the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after acquiring an additional 440,552 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in shares of Jazz Pharmaceuticals by 61.0% in the 2nd quarter. Sei Investments Co. now owns 69,265 shares of the specialty pharmaceutical company’s stock valued at $7,393,000 after purchasing an additional 26,232 shares during the period. Institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JAZZ. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Royal Bank of Canada decreased their price objective on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating for the company in a report on Thursday, August 1st. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Needham & Company LLC reissued a “buy” rating and issued a $205.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $173.07.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $111.41 on Tuesday. The company has a market cap of $7.03 billion, a PE ratio of 22.97, a price-to-earnings-growth ratio of 1.36 and a beta of 0.57. The firm has a 50-day moving average of $111.02 and a 200-day moving average of $110.74. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $137.38. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. As a group, equities analysts forecast that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current year.

Insider Activity

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.